Clinical and Economic Outcome of Simvastatin in Critically Ill Septic Patient

NCT02067949 ↗

Phase 3 Completed 100 enrolled sara mostafa amin eladawy

RandomizedParallel-groupDouble-blindTreatment

Summary

determination of the effectiveness and the cost-effectiveness of simvastatin(Zocor 40 mg) plus standard therapy (SSCG)versus standard therapy alone in critically ill septic patient from the societal perspective over one year.

Timeline

Start: 2014-02
Primary completion: 2015-02
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Simvastatin	Small molecule	40 mg	Oral

Clinical and Economic Outcome of Simvastatin in Critically Ill Septic Patient

Summary

Timeline

Drugs

Indications